Today’s deal with Blueprint gives Ipsen two shots at Fop, but makes its takeout of Clementia look even more expensive.
Healx's "hypothesis-free" approach proves a big draw to investors despite the early-stage nature of the group's projects.
Fresh from buying omaveloxolone and bardoxolone rights back from Abbvie, Reata sees the first part of the puzzle fall into place.
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
Innovate combines with RDD, but the success of the takeover relies in large part on a project for coeliac disease.